Syros Pharmaceuticals, Inc.
SYRS · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $386 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $325 | $331 | $334 | $279 |
| Gross Profit | -$325 | -$331 | -$334 | $107 |
| % Margin | – | – | – | 27.7% |
| R&D Expenses | $20,527 | $21,953 | $24,321 | $21,224 |
| G&A Expenses | $5,655 | $5,463 | $6,266 | $5,888 |
| SG&A Expenses | $5,655 | $5,463 | $6,266 | $5,888 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $26,182 | $27,416 | $30,587 | $27,112 |
| Operating Income | -$26,182 | -$27,416 | -$30,921 | -$27,005 |
| % Margin | – | – | – | -6,996.1% |
| Other Income/Exp. Net | $19,786 | $4,089 | $27,213 | -$37,244 |
| Pre-Tax Income | -$6,396 | -$23,327 | -$3,708 | -$64,384 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$6,396 | -$23,327 | -$3,708 | -$64,384 |
| % Margin | – | – | – | -16,679.8% |
| EPS | -0.16 | -0.59 | -0.095 | -2.18 |
| % Growth | 72.9% | -520.4% | 95.6% | – |
| EPS Diluted | -0.16 | -0.59 | -0.095 | -2.18 |
| Weighted Avg Shares Out | 39,269 | 39,269 | 38,978 | 29,542 |
| Weighted Avg Shares Out Dil | 39,336 | 39,269 | 38,978 | 29,542 |
| Supplemental Information | – | – | – | – |
| Interest Income | $793 | $1,085 | $1,546 | $1,283 |
| Interest Expense | $1,312 | $1,382 | $1,307 | $1,329 |
| Depreciation & Amortization | $325 | $331 | $334 | $279 |
| EBITDA | -$4,759 | -$21,614 | -$2,067 | -$62,776 |
| % Margin | – | – | – | -16,263.2% |